The sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still remains well below the COVID-19 boom that saw nearly 100 public debuts in 2021. hubs.ly/Q04C1xlq0

The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in. hubs.li/Q04C0XH-0

Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy. hubs.li/Q04C0VD70

Brepocitinib is on a roll. After its autoimmune skin disease approval, Roivant subsidiary Priovant’s drug hit all primary and secondary endpoints in two Phase 3 non-infectious uveitis trials, leading analysts to note the agent “looked superior to Humira.” hubs.li/Q04C0TlH0

At the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Alan Northrup says gets the payload release “just right.” hubs.li/Q04C0HGV0

The $100,000 H-1B visa fee has significantly changed who biopharma companies hire, but it’s not the only policy move affecting foreign-born job seekers in the U.S. Dave Bowers (EPM Scientific) and Audrea Golding (Fragomen) discuss the latest developments. hubs.li/Q04C0zQx0

On Denatured, Bruce Culleton, CEO at ProKidney, and Demetri Maxim, CEO at Nephrogen, discuss why kidney disease challenges cell and gene therapies and how delivery strategies, new therapies and regulatory clarity could support commercially viable options. hubs.li/Q04C0q8y0

Funding an academic exit, leaving ecology and evolutionary biology for biomedical engineering, and moving from business development to entrepreneurship shaped 3 careers. hubs.li/Q04B_RsX0

Pfizer is saying goodbye to an unspecified number of employees across its manufacturing operations, a spokesperson confirmed to BioSpace via email on Tuesday. hubs.li/Q04BV6FC0

Looking for a remote biopharma position? Check out the BioSpace list of eight companies hiring life sciences professionals like you. hubs.li/Q04BTFj50

Just one-third of patients prescribed new medicines filled them within 30 days, with a new report from the Institute for Clinical and Economic Review and West Health suggesting that cost is the problem. hubs.li/Q04BTDZd0

Hibsago’s approval—a functional cure for certain patients with a hepatitis B infection—further validates Ionis Pharmaceuticals’ antisense platform, which has already generated two other new drug approvals this year. hubs.li/Q04BTCRy0

Post hoc analyses in women divided by menopausal status show how Novo’s next-generation GLP-1 drug affects key cohorts of patients. hubs.li/Q04BTgQm0

A strong crossover raise can suggest that a company has “reached a level of maturity” and could go public soon, according to Sofinnova Investments’ Jim Healy. hubs.li/Q04BTgf20

China may be taking the majority of licensing deals this year but those transactions don’t tell the whole story, according to Locust Walk, which points to the spike in M&A among U.S. biotechs as leveling the playing field. hubs.li/Q04BTf6H0

Compensation can feel like a verdict on your value. Executive coach Angela Justice explains why companies are usually pricing the job, not the person doing it—and how understanding the difference can help you make better career decisions. hubs.li/Q04BT7ST0

Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential pipeline-in-a-product—this time showing improvement in symptoms of bipolar mania. hubs.li/Q04BLx5Y0

Enlivex is cutting about 60% of staff to reduce costs and focus on mid-stage development of its knee osteoarthritis cell therapy, Allocetra. After another disappointing duravyu readout in wet AMD, EyePoint is reprioritizing and cutting about 53% of staff. hubs.li/Q04BLnPS0

METiS TechBio’s AiLNP platform uses machine learning models to develop lipid nanoparticles with potentially better tissue specificity that could enhance a drug’s therapeutic performance.

Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolstering the company’s push beyond its HIV portfolio. hubs.li/Q04BK06b0